Viper 101
Alternative Names: Viper-101Latest Information Update: 13 Dec 2024
Price :
$50 *
At a glance
- Originator viTToria Biotherapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Non-Hodgkin's lymphoma; T-cell lymphoma
Most Recent Events
- 09 Dec 2024 Pharmacodynamics data from a preclinical trial in T-cell lymphoma released by Vittoria Biotherapeutics
- 22 Jul 2024 Phase-I clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA (IV) (NCT06420089)
- 27 Feb 2024 Phase-I clinical trials in T-cell lymphoma (Second-line therapy or greater) in USA (Parenteral) (prior to February 2024)